Table 4.
Crude and overlap propensity score weighted odds ratios of dates of statin prescription for benign brain tumors.
| Characteristics | N of Brain Tumors |
N of Controls |
Odds Ratios for Benign Brain Tumors (95% Confidence Interval) | |||
|---|---|---|---|---|---|---|
| (Exposure/Total, %) | (Exposure/Total, %) | Crude | p-Value | Overlap Weighted Model † | p-Value | |
| Dyslipidemia and Any statin prescription | ||||||
| Normal | 435/821 (52.98) | 1861/3284 (56.67) | 1 | 1 | ||
| Dyslipidemia without statin | 191/821 (23.26) | 865/3284 (26.34) | 0.94 (0.78–1.14) | 0.553 | 0.95 (0.82–1.11) | 0.556 |
| Dyslipidemia with <365 days | 96/821 (11.69) | 231/3284 (7.03) | 1.78 (1.37–2.31) | <0.001 * | 1.75 (1.39–2.21) | <0.001 * |
| Dyslipidemia with ≥365 days | 99/821 (12.06) | 327/3284 (9.96) | 1.30 (1.01–1.66) | 0.041 * | 1.34 (1.08–1.68) | 0.009 * |
| Dyslipidemia and Lipophilic statin prescription | ||||||
| Normal | 435/821 (52.98) | 1861/3284 (56.67) | 1 | 1 | ||
| Dyslipidemia without Lipophilic statin | 229/821 (27.89) | 981/3284 (29.87) | 1.00 (0.84–1.19) | 0.988 | 1.02 (0.88–1.18) | 0.84 |
| Dyslipidemia with <365 days | 80/821 (9.74) | 208/3284 (6.33) | 1.65 (1.25–2.17) | <0.001 * | 1.59 (1.24–2.03) | <0.001 * |
| Dyslipidemia with ≥365 days | 77/821 (9.38) | 234/3284 (7.13) | 1.41 (1.07–1.86) | 0.016 * | 1.44 (1.12–1.84) | 0.004 * |
| Dyslipidemia and Hydrophilic statin prescription | ||||||
| Normal | 435/821 (52.98) | 1861/3284 (56.67) | 1 | 1 | ||
| Dyslipidemia without Hydrophilic statin | 322/821 (39.22) | 1231/3284 (37.48) | 1.12 (0.95–1.31) | 0.171 | 1.11 (0.96–1.27) | 0.151 |
| Dyslipidemia with <365 days | 43/821 (5.24) | 109/3284 (3.32) | 1.69 (1.17–2.44) | 0.005 * | 1.64 (1.19–2.25) | 0.002 * |
| Dyslipidemia with ≥365 days | 21/821 (2.56) | 83/3284 (2.53) | 1.08 (0.66–1.77) | 0.751 | 1.14 (0.76–1.70) | 0.526 |
Abbreviations: CCI, Charlson Comorbidity Index; * Significance at p < 0.05; † Adjusted for age, sex, income, region of residence, diabetes history, CCI scores, and diabetes.